Type 2 inflammation is the underlying cause of CRSwNP in 80% of patients. CRSwNP is predominantly characterized by type 2 inflammation of the nose and paranasal sinuses and is frequently associated with comorbidities of the lower airway. By inhibiting IL-4 and IL-13 signaling, DUPIXENT targets both upper and lower airway inflammation in CRSwNP and asthma.2-5,a

DUPIXENT is indicated as an add-on maintenance treatment of adult and pediatric patients aged 6 years and older with moderate-to-severe asthma characterized by an eosinophilic phenotype or with oral corticosteroid dependent asthma. Limitation of Use: DUPIXENT is not indicated for the relief of acute bronchospasm or status asthmaticus.

a In Western countries.

CRSwNP, chronic rhinosinusitis with nasal polyposis.

Explore the upper and lower airway